Showing results (1-10 of 44) with videos related to
Sort By:
Pageof 5
The Journal of Infectious Diseases|January 5, 2002
Search for polymorphisms in the genes for herpesvirus entry mediator, nectin-1, and nectin-2 in immune seronegative individualsFrank Struyf, Christine M Posavad, Els Keyaerts, et al.Vaccine|August 2, 2011
Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2Christine M Posavad, Amalia S Magaret, Lin Zhao, et al.The Journal of Infectious Diseases|July 24, 2004
Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapyChristine M Posavad, Anna Wald, Steven Kuntz, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2003
CTL are inactivated by herpes simplex virus-infected cells expressing a viral protein kinaseDerek D Sloan, George Zahariadis, Christine M Posavad, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 19, 2010
Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative personsChristine M Posavad, Michael Remington, Dawn E Mueller, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 12, 2003
T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?Christine M Posavad, Anna Wald, Nancy Hosken, et al.Clinical and Vaccine Immunology : CVI|September 12, 2008
Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection systemAshok Cattamanchi, Christine M Posavad, Anna Wald, et al.Frontiers in Immunology|April 18, 2022
HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV AntigensDavid M Koelle, Lichun Dong, Lichen Jing, et al.Vaccine|September 30, 2025
SARS-CoV-2 spike sequence-based distance as a marker of binding antibody response to COVID-19 vaccinesClara P Dominguez Islas, Craig A Magaret, Cindy Molitor, et al.Nature Communications|April 15, 2026
SARS-CoV-2 vaccination and infection elicit cross-neutralizing responses against clade 3 and 4 sarbecovirusesStephen D Schmidt, Rahul Subramanian, Manjula Basappa, et al.Pageof 5